Exec Chat: 'Wow Factor' Is Important in Medtech Investment, But It’s Not Everything Says Ceros CEO

'There is a Revolution In Medtech And Money On the Sidelines,’ Ceros’ Mark Goldwasser told Medtech Insight in an interview

Medtech Insight interviewed the CEO of Ceros Financial Services and its investment banking division, Ceros Capital Markets, about the firm’s considerations for funding early-stage medtechs, and outlook for medtech fundraising, in this uncertain economic climate.

Mark Goldwasser
• Source: Ceros Financial Services

Mark Goldwasser, CEO of New York-based asset management firm Ceros Financial Services, thinks there is a revolution starting in the medtech industry, money on the sidelines, and opportunities to be had in this post-Covid world.

Goldwasser recently talked to Medtech Insight about the company’s investment portfolio and outlook for medtech investment, which has been facing...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Investor Eye

More from Business

Ceryx Medical Amasses £11M To Develop Adaptive Cardiac Pacing Technology

 

The Development Bank of Wales and London-based Parkwalk Advisors led an investment round of £5m, almost doubling Ceryx Medical's total investment to date.

SS Innovations’ SSI Mantra 3 Poised To Challenge Da Vinci In Robotic Surgery Market

 
• By 

SS Innovations reported its first SSi Mantra 3 robotic cardiac surgery in South America as it prepares to file for US FDA de novo clearance and a CE mark. The firm aims to challenge Intuitive Surgical with a lower-cost, flexible system targeting US and European markets.

Innovative Wants Injunction Against J&J Subsidiary After $442M Antitrust Verdict

 
• By 

Innovative Healthcare is asking for a permanent injunction against Johnson & Johnson subsidiary Biosense Webster after winning a $442 million antitrust verdict. The injunction aims to prevent continued anticompetitive practices in the electrophysiology catheter market.